NDTV Profit-Latest Dr Reddy's To Earmark Rs 1,500 Crore Capex For Biosimilars, Injectables By चन्द्र कुमार अधिकारी Sunday, November 6, 2022 Comment Dr Reddy's Laboratories has earmarked a capex of around Rs 1,500 crore for FY23 with major part of it slated to go into building capacities for its biosimilar and injectable businesses. from NDTV Profit-Latest https://ift.tt/726GaeF Related PostsExplained: Why US Has Always Had Its Nominee As World Bank President"Misleading, Unfortunate": Centre Rubbishes Onion Export Ban ReportsIndia's Economic Growth Appears To Be "Very Fragile": RBI Panel MemberPlatforms Like ChatGPT Won't Replace Jobs, Will Be A Co-Worker: TCS
0 Response to "Dr Reddy's To Earmark Rs 1,500 Crore Capex For Biosimilars, Injectables"
Post a Comment